Kaplan Meier time to significant fibrosis stratified by sex.

<p>Kaplan Meier time to significant fibrosis stratified by sex.</p

Participant Selection Flow Chart.

<p>Participant Selection Flow Chart.</p

Discrete time proportional hazards models of factors associated with development of significant fibrosis (APRI ≥ 1.5) in follow-up.

<p>Abbreviations: IDU, injection drug use; HCV, hepatitis C virus; cART, combination antiretroviral; PI, protease inhibitor;</p><p>NNRTI, non-nucleoside reverse transcriptase inhibitor; APRI, aspartate aminotransferase to platelet ratio;</p><p>BMI, body mass index; HR, hazard ratio; CI, confidence interval.</p><p>Discrete time proportional hazards models of factors associated with development of significant fibrosis (APRI ≥ 1.5) in follow-up.</p

Sociodemographic and clinical characteristics of HIV-HCV co-infected patients at baseline by sex (2003–2012).

<p>Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use;</p><p>APRI, aspartate aminotransferase to platelet ratio; AST, aspartate aminotransferase; BMI, body mass index;</p><p>cART, combination antiretroviral; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor.</p><p>^aSum of regimens >100% as some participants are on both PI, NNRTI and/or other cART.</p><p>^bFor HCVRNA VL only 166 (34/87 (39%) female and 132/221 (60%) male) had available quantitative HCV RNA values.</p><p>Sociodemographic and clinical characteristics of HIV-HCV co-infected patients at baseline by sex (2003–2012).</p

Efficacy of therapy by regimen in A) in ARV-naive, and B) ARV-experienced, virologically suppressed patients.

<p>Percentage indicated shows subjects with HIV-1 RNA <50 copies/mL at week 48. Studies that were randomised and sufficiently powered for direct comparison of standard and dual therapy regimens are shaded. ¹<48 copies/mL; ²at 96 weeks; ³<40 copies/mL; ⁴at 96 weeks; ⁵<48 copies/mL; ⁶at 96 weeks; ⁷at 24 months; ⁸at 12 months; ⁹at week 24; ¹⁰<80 copies/mL. ARV, antiretroviral.</p

Study designs for identified trials in ARV-experienced, virologically suppressed patients.

<p>Study designs for identified trials in ARV-experienced, virologically suppressed patients.</p

Results of key virologic endpoints from identified trials in ARV-naive patients¹.

<p>Results of key virologic endpoints from identified trials in ARV-naive patients<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0148231#t002fn002" target="_blank">¹</a>.</p

Study designs for identified trials in ARV-naive patients.

<p>Study designs for identified trials in ARV-naive patients.</p

Results of key secondary endpoints from identified trials among ARV-experienced HIV-suppressed patients.

<p>Results of key secondary endpoints from identified trials among ARV-experienced HIV-suppressed patients.</p

Flow diagram of literature search for systematic review.

<p>Flow diagram of literature search for systematic review.</p